PET brain scan study for several brain and mood conditions
Part of Brain & nervous system, Immune system & allergy, Mental health clinical trials.
This early-phase study uses PET and MRI brain scans to better understand brain changes in multiple sclerosis, Alzheimer’s disease, and other neurological or mood conditions. The goal is to test whether these scans can show disease-related differences and guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 70 years old (Alzheimer’s and healthy controls may be up to 85)
- Have the right diagnosis for the group you’re screened for (such as active multiple sclerosis or worsening disability score)
- Be able to undergo both PET and MRI scans
- Be willing and able to sign informed consent
- If in certain treatment groups: you must have been prescribed the treatment but not started the first dose yet
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study uses special brain scans (PET and MRI) to measure “synapse density” (how many connection points brain cells have) in people with multiple sclerosis (MS). It may help researchers understand MS biology and improve future treatments.
This Phase 1 study tests a special tracer used during MRI and PET scans to look at brain changes in people with multiple sclerosis. It’s mainly aimed at improving how these scans can detect disease-related changes and confirming the tracer works safely.
This study uses a special PET-MRI scan to look at brain inflammation in people with relapsing-remitting multiple sclerosis (RRMS). It may help researchers understand how inflammation changes when starting a stronger MS treatment.
This early-stage study tests an imaging medicine ([F-18]DPA-714) that can help researchers see inflammation in the brain and nervous system. It may help doctors better understand how “inflammation signals” differ across conditions like multiple sclerosis, fibromyalgia, and chronic fatigue syndrome.
This Phase 1 study tests a PET scan to measure inflammation-related changes in the brain using a medication called ketoprofen. It may help researchers understand which people with certain brain diseases could benefit from treatments aimed at inflammation.
This trial compares scan results in people with multiple sclerosis or related demyelinating conditions versus people without inflammatory demyelinating diseases. The goal is to better understand what’s happening in the brain and how sex differences may play a role.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.